Operations

Media call 11 am, Garvan Institute with researchers and the late Rebecca Wilson’s brother, Jim Wilson

Meet in the foyer of the Kinghorn Cancer Centre, 370 Victoria St, Darlinghurst NSW 2010

• Images
• Footage

Researchers are recruiting volunteers for a clinical trial they hope will improve survival rates for an aggressive form of breast cancer that affects about 1,500 women each year in New South Wales.

The trial will test a new strategy in cancer treatment: using a new therapy to target a ‘defence switch’ on cancer cells that alerts cancer to the threat of chemotherapy.

The trial aims to improve survival rates for patients with triple negative breast cancer, a treatment-resistant form of cancer that can quickly adapt against chemotherapy. It will commence in August.

It will be led by Associate Professor Christine Chaffer and Dr Beatriz San Juan from the Garvan Institute of Medical Research, and Senior Staff Specialist in medical oncology Dr Rachel Dear of St Vincent’s Hospital Sydney. The trial will be conducted at The Kinghorn Cancer Centre in Darlinghurst.

Australian researchers uncover hidden genetic markers of glaucoma.

Stem cell models of the retina and optical nerve have been used to identify previously unknown genetic markers of glaucoma, in research jointly led by scientists from the Garvan Institute of Medical Research, the University of Melbourne, and the Centre for Eye Research Australia. The findings open the door to new treatment for glaucoma, which is the world’s leading cause of permanent blindness.

“We saw how the genetic causes of glaucoma act in single cells, and how they vary in different people. Current treatments can only slow the loss of vision, but this understanding is the first step towards drugs that target individual cell types,” says Professor Joseph Powell, joint lead author at the Garvan Institute of Medical Research.

The research, published today in the journal Cell Genomics, comes out of a long-running collaboration between Australian medical research centres to use stem-cell models to uncover the underlying genetic causes of complicated diseases.